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We have identified novel adjuvant activity in specific cytosol fractions from trophozoites of Giardia isolate
BRIS/95/HEPU/2041 (J. A. Upcroft, P. A. McDonnell, and P. Upcroft, Parasitol. Today, 14:281–284, 1998).
Adjuvant activity was demonstrated in the systemic and mucosal compartments when Giardia extract was
coadministered orally with antigen to mice. Enhanced antigen-specific serum antibody responses were dem-
onstrated by enzyme-linked immunosorbent assay to be comparable to those generated by the “gold standard,”
mucosal adjuvant cholera toxin. A source of adjuvant activity was localized to the cytosolic component of the
parasite. Fractionation of the cytosol produced fraction pools, some of which, when coadministered with
antigen, stimulated an enhanced antigen-specific serum response. The toxic component of conventional mu-
cosal adjuvants is associated with adjuvant activity; therefore, in a similar way, the toxin-like attributes of
BRIS/95/HEPU/2041 may be responsible for its adjuvanticity. Complete characterization of the adjuvant is
under way.
Vaccination, conventionally by the parenteral route, has
proven to be the most effective means of protecting a popula-
tion and individuals from infectious disease. More recently,
focus on the dangers involved with needle injection, including
multiple use, hepatitis, and human immunodeficiency virus
infection, and the expense and fear of needles, particularly in
Third World countries, have dictated the need for alternative
vaccination routes, such as the practical, noninvasive oral
route.
Oral delivery requires that the vaccine preparation survive
stomach acid and digestive enzymes to arrive intact at the
desired site on the digestive tract and to overcome the phe-
nomenon of oral tolerance. Successful delivery is frequently
dependent on coadministration of an adjuvant for stimulation
of an immune response. Traditionally, orally delivered or mu-
cosal adjuvants have included bacterial ligands and toxins, such
as Escherichia coli labile toxin (LT), cholera toxin (CT), and
CT B subunit (CT-B) (22). These adjuvants have the ability to
bind to intestinal epithelial cells and abrogate oral tolerance to
coadministered or covalently coupled antigens (14). However,
due to their toxicity, neither CT nor LT is suitable for human
use. Alternative mutant toxin molecules (22), including recom-
binant forms (29) and fusion proteins (1, 30), have been de-
rived, but are often not as effective mucosally when lacking the
toxic A1 subunit, with maximal mucosal immunoglobulin A
(IgA) responses achieved in the presence of whole CT (13, 22).
Additionally, a number of inert delivery systems, including
gelatin capsules (21), microspheres or microparticles (15, 18),
and bioadhesive preparations (25), improve vaccine efficacy
by allowing intact delivery of the vaccine to the gut mucosa,
but are generally without adjuvant activity. Cytokines (2, 8),
recombinant bacterial and viral vectors (11, 12), oligode-
oxynucleotides (17, 20), immune response-stimulatory com-
plexes (ISCOMS) and lipid derivatives (3, 4, 26), alkyl-polyac-
rylate esters (16), and other candidate adjuvants and delivery
mechanisms (35), including transgenic vegetables (28), have
been assessed for mucosal delivery in animal models, with
some advancing to human trials. However, the only adjuvants
currently approved for human use are aluminum salts and
MF59 (24), and the only vaccines routinely used for oral de-
livery are the live attenuated polio vaccine, the live attenuated
Salmonella enterica serovar Typhi vaccine, and the tetravalent
rotavirus vaccine, which is currently in doubt (34). Clearly
there is much ongoing development of mucosal vaccination
strategies. However, the toxicity of existing mucosal adjuvants
and the limited range approved for human use, along with
other issues (24), including effective dose requirements, stabil-
ity, and economic measures, warrants additional investigation
of putative adjuvants for human administration.
We have previously described an isolate of Giardia duode-
nalis (BRIS/95/HEPU/2041), referred to as 2041, established
from a bird which died of an overwhelming infection with the
parasite (31). Isolate 2041 chronically infects mice and pro-
duces higher peak parasite loads than the human Giardia iso-
late BRIS/83/HEPU/106 (referred to as 106) (31, 32). Mice
infected with 2041 suffer weight gain impairment, with the
most severe weight deficit occurring at the time of maximum
parasite load (32). Total serum IgA levels of these mice are
threefold higher than those from mice infected with 106 tro-
phozoites, but their specific anti-Giardia serum IgA and IgM
* Corresponding author. Mailing address: Division of Infectious
Diseases and Immunology, Queensland Institute of Medical Research,
PO Royal Brisbane Hospital, Queensland 4029, Australia. Phone: 61-
7-3362 0375. Fax: 61-7-3362 0105. E-mail: lindaD@qimr.edu.au.
† Present address: Army Malaria Institute, Gallipoli Barracks,
Enoggera, Qld, Australia.
‡ Present address: Environmental Engineering Department, Griffith
University, Nathan, Qld, Australia.
6503
levels are significantly decreased (36). Weight loss is often
associated with production of toxins by bacteria residing in or
in transit through the gut. In general these toxins act by alter-
ing electrolyte transport across the intestinal mucosa, resulting
in water loss and thus weight loss in animals (23). The toxin
gene homologue overexpressed in parasites under drug pres-
sure (10), our Giardia 2041 studies (31, 32, 36), and the body of
literature equating some toxins with adjuvants (27, 13) have led
to the current assessment of Giardia isolate 2041 adjuvanticity.
The toxin gene homologue identified in a G. duodenalis labo-
ratory isolate encodes a protein which has 57% homology with
the gene encoding the precursor of the sarafotoxins, a group of
snake toxins from the burrowing adder known to cause symp-
toms similar to those in humans acutely infected with Giardia
(10). While identification of this gene in the 2041 isolate is still
under investigation, these data demonstrate that Giardia iso-
lates may be capable of producing toxins as part of their in-
fective process, which in turn might display adjuvant activity.
This paper describes initial data on oral administration of
antigen with various preparations of Giardia extracts and dem-
onstrates antigen-specific mucosal and systemic adjuvant activ-
ity provided by the cytosolic component of Giardia isolate 2041
trophozoites.
MATERIALS AND METHODS
Mice. Inbred C57BL/6J, hybrid C57BL/6J  CBA, and outbred Quackenbush
5- to 8-week-old female mice and pregnant Quackenbush female mice were
obtained from the Animal Resources Centre (Perth, Australia) and housed
under PC2 conditions within Queensland Institute of Medical Research. All
protocols were approved by the Bancroft Centre Research Ethics committee,
according to National Health and Medical Research Council guidelines.
Parasite culture. Trophozoites of G. duodenalis isolates 2041 (31) and 106 (6)
were cultured as previously described (7). Isolate 106 has arbitrarily been des-
ignated the standard laboratory isolate.
Parasitic infection. Quackenbush 3-day-old neonates were each infected via
intragastric tubing (7) with 5  105 trophozoites from either Giardia 2041 or 106
in 50 l of sterile phosphate-buffered saline (PBS) or with sterile PBS alone, and
small intestines were collected at 2 and 3 weeks postinfection. The small intestine
was excised from the duodenum to the cecum, and portions of approximately 10
mm in length were removed from the midpoint of this section, frozen in OCT
(Tissuetech) embedding agent on dry ice, and then stored at 70°C.
Immunohistochemistry. Frozen samples were sectioned in a microtome at
20°C, mounted on treated (1% 3-aminopropyltriethoxy–saline [Sigma] in ace-
tone) glass microscope slides, then fixed in acetone at 20°C for 10 min, and
stored desiccated at 20°C. Fixed sections were brought to room temperature
(RT) and rehydrated in PBS for 5 min. Endogenous peroxidases were blocked
with 0.8% hydrogen peroxide in methanol solution for 3 to 5 min, and the
sections were washed in PBS and then blocked with 0.5% bovine serum albumin
(BSA) in PBS for 1 h at RT. The sections were then incubated with either goat
anti-mouse IgA-horseradish peroxidase (HRP), IgG-HRP, IgM-HRP, or rat
anti-mouse IgE-HRP (Southern Biotechnology Associates Inc.), according to the
manufacturer’s instructions. The detecting antibody was removed with three
washes in PBS, the color was developed using 3,3diaminobenzidine (Sigma Fast
DAB) for 3 to 5 min, and the reaction was stopped with PBS washes. The
sections were counterstained with alcoholic eosin for 45 s, dehydrated with
ethanol, cleared with three washes of xylene, and mounted in dpx (ProSciTech).
Antibody-specific staining was identified by light microscopy.
Antigens and adjuvants. Lyophilized keyhole limpet hemocyanin (KLH) (Sig-
ma) was resuspended in either sodium bicarbonate (pH 9.0) or sterile PBS at the
time of inoculation. Inactivated influenza virus (Flu) strain A/Texas/36/91 (3.25
mg ml1) was supplied by Lorena Brown (Department of Microbiology and
Immunology, Melbourne University, Melbourne, Australia) and stored at 4°C.
CT (Sigma) from Vibrio cholerae was reconstituted to 2 mg ml1 using sterile
Milli-Q water and stored at 4°C.
Giardia trophozoites were harvested (36) from confluent cultures, counted,
and aliquoted at a concentration of 108 ml1 prior to snap freezing and storage
at 70°C. Trophozoites were identified as different when a new stabilate was
used to initiate the culture (2041, 2041B, 2041C, or 2041L). To prepare cytosolic
extract, trophozoites were freeze-thawed two to three times in liquid nitrogen
and sonicated on ice until no intact parasites were evident. This preparation was
centrifuged at 140,000 g for 40 min, and the supernatant (cytosolic extract) was
removed, aliquoted, and snap frozen prior to storage at 70°C. The remaining
pellet (membrane fraction) was resuspended in PBS, microcentrifuged, resus-
pended in an equivalent volume of PBS to that of the cytosolic extract, aliquoted,
and snap frozen prior to storage at 70°C. To collect secretory product, 107
trophozoites were harvested, washed three times with PBS, and resuspended in
PBS for 1 to 5 h at 37°C. Following incubation, the trophozoites were removed
by centrifugation (trophozoite harvest method), and the supernatant was col-
lected and centrifuged at 1,000  g for 10 min at 4°C. The supernatant (secreted
product) was collected, aliquoted, and stored at 70°C. Cytosolic fractions were
prepared by Isabel Roberts (CSL Limited, Melbourne, Australia) from cytosolic
extract using a Q-Sepharose HPXK 16/5 column. Parasite protein was eluted,
producing 72 2.5-ml fractions, which were separated by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE), using 12% polyacrylamide,
and proteins were visualized by silver staining. There was a great diversity of
clearly separated proteins seen between fractions, best exemplified by the 16
fractions shown in Fig. 1. Fractions were pooled into 12 groups as follows; pool
1, fractions 6 to 11; pool 2, fractions 12 to 15; pool 3, fraction 26; pool 4, fraction
27; pool 5, fraction 28; pool 6, fractions 29 to 31; pool 7, fractions 33 to 34; pool
8, fractions 36 to 38; pool 9, fractions 39 to 45; pool 10, fractions 47 to 54; pool
11, fractions 56 to 63; and pool 12, fractions 69 to 72. Pooled fractions were
designated Fx (fraction pool) 1 to 12.
Inoculation regimen. KLH (0.5 to 5 mg per mouse) or Flu (100 g per mouse)
antigen was prepared alone or with CT (1 or 10 g per mouse) or with Giardia
preparations. In every case the amount of Giardia extract or secreted product
administered to individual mice was derived from 107 trophozoites. This value is
the maximum number of isolate 106 trophozoites which colonize a mouse intes-
FIG. 1. Giardia 2041 cytosolic fractions separated on SDS-PAGE gels (12% acrylamide) and silver stained demonstrate diverse protein profiles.
M, molecular mass markers (in kilodaltons); lane 1, whole cytosolic extract; lane 2, fraction 7; lane 3, fraction 10; lane 4, fraction 12; lane 5, fraction
13; lane 6, fraction 15; lane 7, fraction 26; lane 8, fraction 27; lane 9, fraction 28; lane 10, fraction 29; lane 11, fraction 31; lane 12, fraction 33; lane
13, fraction 32; lane 14, fraction 36; lane 15, fraction 37; lane 16, fraction 39; lane 17, fraction 40.
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tine in the standard laboratory mouse infection model (32). KLH prepared in
combination with each of the 12 Giardia cytosolic fraction pools or KLH alone
was dialyzed against PBS for 2 h at 4°C to produce a preparation suitable for
administration to mice. Subsequently only the high-salt-containing preparations
(KLH plus Fx12 and KLH plus Fx7) were dialyzed.
Inocula were prepared in sterile PBS or sodium bicarbonate (pH 9.0) to
neutralize stomach acids, and 100 to 200 l was administered per os (p.o.) to
individual mice using Terumo 18-gauge drawing-up needles or via intragastric
tubing (7). Mice inoculated via tubing were anesthetized intraperitoneally (i.p.)
with 100 l each of 20% pentobarbitone sodium (Rhoˆne Me´rieux) in sterile PBS.
For each experiment, mice were dosed using one of three regimens: (i) day 0 and
1 week, (ii) day 0, 1 week, and 3 weeks; and (iii) day 0 and 1, 4, and 6 weeks.
Sample collection and processing. Preimmune fecal and blood (tail vein)
samples were collected from individual mice prior to inoculation. Fecal pellets (4
to 5) and blood samples (10 to 100 l) were routinely collected from individual
mice on a weekly or biweekly basis. Blood, saliva (10 to 100 l), small intestine
(gut) washings (2 ml), and whole small intestines (guts) were collected from each
mouse on experiment termination.
Fecal pellets were collected into preweighed tubes on ice, either for individual
mice or as a pooled group, and processed in 300 l of 0.1-mg ml1 soybean
trypsin inhibitor (STI) (Sigma) prepared in 50 mM EDTA for each 100 mg of
sample. An equivalent volume of cold PBS was added, and a suspension was
produced by vortexing. The samples were then centrifuged at 400  g for 10 min
at 4°C, the supernatant was removed, and 10 l ml1 of 100 mM phenylmeth-
ylsulfonyl fluoride (PMSF) (Sigma) in 95% ethanol was added. The samples were
again vortexed and centrifuged at 4°C. The supernatant was removed, snap
frozen on dry ice, and stored at 70°C.
Blood was collected from the tail vein of each mouse or, on termination, from
the axillary vessels, or by heart puncture, as individual samples or pooled to form
a group sample and allowed to clot overnight at 4°C. Samples were then centri-
fuged at 4°C, and serum was collected, snap frozen on dry ice, and stored at
70°C. For initial experiments (Table 1, Fig. 2, and Fig. 4), blood collected from
individual mice of each inoculation group was pooled and diluted to 5% with
sterile PBS prior to storage at 70°C.
For saliva collection, mice were injected i.p. with 30 to 60 l of a 1.8 mM
solution of pilocarpine (nitrate salt) (Sigma) prepared in sterile PBS to stimulate
salivation. The mice salivated readily 4 to 5 min following treatment, and saliva
was collected by pipette, snap frozen on dry ice, and stored at 70°C. Prior to
assay, saliva samples were thawed on ice, 1 l of 100 mM PMSF was added per
tube, and samples were centrifuged at 4°C.
On experiment termination, the small intestine of each mouse was removed
and washed in sterile PBS, and gut contents were flushed with 2 ml of STI (0.1
mg ml1) and stored on ice. To each 2-ml washing, 10 l of 100 mM PMSF was
added, and the sample was vortexed and centrifuged at 4°C. The supernatant was
collected, snap frozen on dry ice, and stored at 70°C.
After removal of contents, guts were snap frozen on dry ice and stored at
70°C. For processing, frozen guts were placed in a mortar containing liquid
nitrogen and crushed into a powder. Each sample was transferred into 2 ml of
STI (0.1 mg ml1), vortexed, and centrifuged at 400  g for 10 min at 4°C. The
supernatant was transferred to tubes each containing 10 l of 100 mM PMSF,
then vortexed and centrifuged at 4°C. The supernatant was snap frozen on dry ice
prior to storage at 70°C.
Antibody ELISA. Enzyme-liked immunosorbent assay (ELISA) plates were
coated overnight with 2 to 5 g ml1 of antigen (KLH, Flu, or CT) or with a
1:100 dilution of Giardia 2041B cytosolic extract in 50 mM carbonate buffer (pH
9.0) (15 mM Na2CO3, 35 mM NaHCO3, 3 mM NaN3) at 4°C, then washed with
PBS–0.05%Tween 20 (Sigma), and blocking solution containing 0.5% BSA (Sig-
ma) in PBS was added for 1 h at RT. Plates were washed, and samples were
added in dilution buffer (0.05% BSA, 0.05% Tween 20 in PBS) and serially
diluted within the plate. Preimmune sera and fecal samples, and control saliva,
gut washes, and gut homogenate samples collected from either Quackenbush or
C57BL/6J  CBA control mice were included to determine cutoff values for
antibody titers.
Plates were incubated at 37°C for 1 h in a humidified chamber or overnight at
4°C and then washed. Secondary antibodies, goat anti-mouse IgA-HRP and
IgG-HRP (Southern Biotechnology Associates Inc.) and unlabeled rabbit anti-
mouse IgA and IgG (Southern Biotechnology Associates Inc.), were added to the
plate at a 1:2,000 dilution, according to the manufacturer’s instructions, followed
by a 1-h incubation at 37°C or a 6-h incubation at RT. To assess IgG subsets,
HRP-conjugated sheep anti-mouse IgG1, IgG2a, IgG2b, or IgG3 antibodies
(The Binding Site, Birmingham, United Kingdom) were added to the plate at a
1:3,000 dilution, according to the manufacturer’s instructions, and incubated as
described above. Plates were washed, and alkaline phosphatase-conjugated
sheep anti-rabbit Ig (Southern Biotechnology Associates Inc.) was added, ac-
cording to manufacturer’s instructions, to plates containing unlabeled antibody
for 1 h at 37°C.
3,3,5,5-Tetramethylbenzidine (TMB) peroxidase substrate (KPL Laborato-
ries) was added to plates incubated with HRP-conjugated antibodies and allowed
to develop for 1 to 5 min. The reaction was stopped with 100 l per well of 0.5
M sulfuric acid, and optical density (OD) was read at 450 nm using an automated
plate reader. Plates containing alkaline phosphatase-conjugated antibodies were
washed, and p-nitrophenyl phosphate (1 mg ml1 in 10% diethanolamine [pH
9.8]) was added for 20 to 30 min at RT. The plates were then read at an OD of
415 nm using an automated plate reader.
Assays to calculate total IgA concentrations proceeded as follows. ELISA
plates were coated with unlabeled goat anti-mouse IgA (Southern Biotechnology
Associates Inc.) according to the manufacturer’s instructions and incubated
overnight at 4°C. Plates were washed and blocked as previously described. Mouse
IgA isotype control, purified antibody (Southern Biotechnology Associates Inc.),
was used as a standard and added to the plate in triplicate over a range of
dilutions from 256 to 0.25 ng ml1. Gut homogenate samples were diluted
1:10,000 and added to the plate in triplicate. Following a 1-h incubation at 37°C,
plates were washed, and goat anti-mouse IgA-HRP was added as previously
described, and the assay was completed in the usual manner (see above).
Total IgA was determined for average gut homogenate OD values using a
curve generated from IgA standards, and results were recorded at a 1:10,000
dilution.
Calculation of titers. Three times the background OD at 415 nm or 450 nm
reading from control samples was used as a cutoff to determine antibody titers.
For the Flu experiments, titers were calculated using the mean  three standard
deviations of the OD450 reading from preimmune samples at each dilution as a
cutoff value. All serum titers are presented on a logarithmic scale and secretory
titers on an arithmetic scale, which best demonstrate the range of titers from
these extracts. All mean values have been calculated arithmetically.
FIG. 2. Trophozoite-adjuvanted anti-KLH serum IgG titers vary
relative to Giardia isolate. Groups of four Quackenbush mice were
inoculated with 3 mg of KLH alone or with 107 trophozoites on days 0
and 7. Pooled serum samples were collected from each group on days
14, 21, and 28, and anti-KLH serum IgG titers were detected by ELISA.
TABLE 1. Giardia trophozoite adjuvanted KLH-specific
antibody responsea
Inoculum
Titer
Ser IgG Ser IgA Fec IgA
KLH 6500 320 92
KLH  2041 20,000 10,240 400
a Groups of four to six Quackenbush mice were inoculated with 5 mg of KLH
alone or with 107 2041 trophozoites on days 0, 7, and 21. Pooled fecal (Fec) and
serum (Ser) samples from each group were collected on day 31.
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RESULTS
Adjuvant activity of Giardia trophozoites. To assess the ad-
juvant activity of Giardia trophozoites, we coadministered to
mice whole Giardia 2041 or 106 trophozoites with KLH anti-
gen using a two-dose regimen and observed an increase in
anti-KLH serum IgG titers over those detected for mice inoc-
ulated with KLH alone (Fig. 2). By experiment day 28, anti-
KLH serum IgG titers were twofold higher for the 2041 group
(20,480) compared with the 106 group (10,240) (Fig. 2). When,
using the same parameters, 2041B trophozoites were coadmin-
istered with a range of KLH concentrations, anti-KLH serum
IgG titers measured on experiment day 28 diminished relative
to antigen dose as follows; 5,120 at 3 mg/mouse, 2,560 at 1
mg/mouse, 1,280 at 0.5 mg/mouse, and 1,280 at 0.5 mg/mouse
of nonadjuvanted KLH. Increased concentrations of KLH (up
to 5 mg/mouse), coadministered with Giardia trophozoites, did
not appreciably increase the anti-KLH serum IgG titers (data
not shown).
When KLH was coadministered with 2041 trophozoites us-
ing a three-dose regimen, enhanced anti-KLH serum IgG and
IgA and anti-KLH fecal IgA titers were detected (Table 1).
The enhanced anti-KLH fecal IgA titers were indicative of
adjuvant activity in the mucosal compartment. To further as-
sess the effect of Giardia trophozoites on the secretion of
mucosal antibodies, intestinal sections were taken from neo-
natal mice infected with 2041 or 106 trophozoites and stained
for antibodies at 2 and 3 weeks postinfection. The density of
IgA staining was greater at 2 weeks postinfection for tropho-
zoite-infected mice over control mice (Fig. 3). In most sections
from 2041-infected mice, the staining density appeared greater
compared to the 106-infected mice. By 3 weeks postinfection,
IgA staining was detected at the same level in all groups,
including the control group (data not shown). There was no
specific staining for IgE and IgM antibodies at each time point
tested (data not shown). Mucosal IgG was not detected at 2
weeks postinfection but was demonstrable in sections from all
inoculation groups at approximately the same density of stain-
ing at 3 weeks postinfection (data not shown).
Adjuvant activity of Giardia 2041 crude extracts. Using a
freeze-thaw and sonication technique, Giardia trophozoites
were fractionated into membrane and cytosolic extracts. We
coadministered 2041 trophozoites, cytosolic extract, or mem-
brane fraction with KLH antigen using a three-dose regimen.
Anti-KLH serum IgG titers peaked on experiment day 28 (Fig.
4A), with titers from the cytosolic extract and trophozoite
groups (20,000) being greater than from the membrane frac-
tion (2,000) and KLH alone (6,500) groups. An anti-KLH
serum IgG1 and IgG2b response was detected, while there was
no measurable anti-KLH serum IgG2a or IgG3. Anti-KLH
serum IgG1 peaked by day 31 and anti-KLH serum IgG2b by
day 35 in the trophozoite- and cytosolic extract-adjuvanted
groups (data not shown).
An anti-KLH serum IgA response peaked on day 28, with
titers from the cytosolic extract and trophozoite groups
(10,240) being greater than those measured from the mem-
brane fraction and KLH-alone groups (320) (Fig. 4B). The
enhanced anti-KLH serum IgG and IgA responses remained
constant until at least experiment day 35.
An anti-KLH fecal IgA response peaked by experiment day
31, with the highest titer measured from the 2041 cytosolic
extract group (3,200) (Fig. 4C). Although the anti-KLH fecal
IgA titer was lower in the trophozoite group (400), it was at
least four times greater than the titer measured from the mem-
brane fraction and KLH-alone groups (Fig. 4C). Compara-
tively, when 106 cytosolic extract was coadministered to mice
with antigen, there was no enhancement of secretory IgA titers
over those recorded for the antigen-alone group (data not
shown).
Secreted product from 2041 and 106 trophozoite cultures
was coadministered to mice with KLH antigen, but resulted in
no significant increase in anti-KLH serum or fecal antibody
titers over those from the group administered KLH alone (data
not shown).
Reproducibility of Giardia 2041 adjuvant activity. Our find-
ings thus far have demonstrated that the cytosolic fraction of
Giardia 2041 trophozoites, rather than the membrane fraction
or secreted product, is the predominant source for adjuvant
activity. We subsequently assessed the reproducibility of this
activity through comparing antibody responses in mice admin-
istered antigen and different batches of 2041 cytosolic extract,
FIG. 3. Total mucosal IgA measured on the intestinal mucosa of Giardia trophozoite-infected mice. Three-day-old Quackenbush mice were
each inoculated p.o. with one dose of either Giardia 2041 (C) or 106 (B) trophozoites (5  105 per mouse) or with PBS (A) as a control. The small
intestine was collected at 14 days postinfection, and IgA was bound with goat anti-mouse IgA-HRP antibody. The bar in each panel represents
100 m.
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measuring antibody titers from individual mice rather than
from pooled groups, and comparing the level of Giardia adju-
vant activity with the “gold standard” control adjuvant, CT.
Three batches of Giardia 2041 trophozoites were used to
produce cytosolic extracts (2041C, 2041B, and 2041L), which
were administered to mice with KLH using a two-dose regi-
men, and directly compared with CT for enhancement of anti-
KLH serum IgG titers. By experiment day 20, anti-KLH serum
IgG titers from the cytosolic extract-adjuvanted groups were
on average five to six times greater (50,000 to 58,000) than
those from the KLH alone group (10,000). The average anti-
KLH serum IgG titer from the CT-adjuvanted group was three
to four times greater (200,000) than the cytosolic extract-ad-
juvanted group’s and 20 times greater than the KLH-alone
group’s. Earlier, on experiment day 13, a similar pattern of
results was seen, but with some differences in response be-
tween the cytosolic extract-adjuvanted groups. Overall, the dif-
ferent batches of cytosolic extract produced similar results and
demonstrated adjuvant activity.
Variation in Giardia adjuvant activity with antigen. To con-
firm that the enhanced antibody responses seen with adminis-
tration of KLH and Giardia crude extracts were not confined
to one antigen, we repeated our studies using influenza virus
(Flu). In contrast to KLH, there was no significant increase in
anti-Flu serum IgG titers in the Giardia cytosolic extract- or
CT-adjuvanted groups measured 1 week after three doses
(data not shown). Flu is a strong antigen in its own right, and
after four doses, by experiment day 58, average anti-Flu serum
IgG titers had increased in all groups, with only the CT-adju-
vanted group titer (45,900) above that of the Flu-alone group
(24,400).
Anti-Flu serum IgA titers measured at 1 week after three
doses were low in comparison with those measured for KLH,
with the highest average anti-Flu serum IgA titer, 675, re-
corded for the CT-adjuvanted group. The nonadjuvanted Flu-
alone group titer was 281. Subsequent to four doses, by exper-
iment day 58, the average anti-Flu serum IgA titers measured
from the CT-adjuvanted (1,505) and cytosolic extract-adju-
vanted (1,370) groups were enhanced compared to the Flu-
alone group (613) (Fig. 5A).
To assess the Flu-specific secretory response, we measured
anti-Flu secretory IgA in extracts of saliva, fecal pellets, gut
washings, and gut homogenates at 1 to 2 weeks subsequent to
dose 4. A variable number of responders were identified from
each inoculation group when saliva, fecal extracts, and gut
washing samples were assessed, with no convincing uniform
increase in titers in the adjuvanted groups (data not shown).
The highest anti-Flu secretory IgA titers were detected from
gut homogenate extracts, with titers widely spread in the Gi-
ardia-adjuvanted and Flu-alone groups (Fig. 5B). The Giardia-
adjuvanted group had the highest average titer of 13,000,
compared to a titer of 8,500 for the Flu-alone group and
6,700 for the CT-adjuvanted group (Fig. 5B).
Levels of total IgA were assessed in the gut homogenate
samples to ascertain a correlation between these results and
the variable anti-Flu secretory IgA titers detected for individ-
ual mice within the same inoculation group. Although total
IgA concentrations varied somewhat between individual mice,
there was no apparent association between level of Flu-specific
antibody titer and total IgA concentration (data not shown). In
addition, the average ( standard deviation) concentration of
total IgA (in a 1:10,000 dilution) was similar for each of the
inoculation groups as follows: Flu, 35.6  12.6 ng/ml; CT-
adjuvanted group, 31.2  16.4 ng/ml; and Giardia-adjuvanted
group, 30.5  10.4 ng/ml. Use of an inbred mouse strain
(C57BL/6J) also did not increase the uniformity in response
between individual mice from each group.
Adjuvant activity of fractions from Giardia 2041 cytosol. To
further investigate Giardia adjuvant activity, 2041 cytosolic ex-
tract was fractionated, and samples of pooled fractions 1 to 12
were prepared, which were subsequently coadministered with
KLH to mice using a two-dose regimen. CT was also coadmin-
istered with KLH, producing a control adjuvant group.
By 2 to 3 weeks after dosing, pooled serum samples dem-
FIG. 4. KLH-specific antibody titers from mice inoculated with an-
tigen and crude Giardia extracts. Groups of six Quackenbush mice
were inoculated with 5 mg of KLH alone or with Giardia extracts from
107 2041 trophozoites on days 0, 7, and 21. Serum and fecal samples
were collected on days 0, 7, 31, and 35 and pooled for antibody
detection by ELISA. Tr, trophozoites; Cyt, cytosolic extract; Mem,
membrane extract.
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onstrated an enhanced anti-KLH serum IgG response for 8 of
the 12 pooled fraction groups tested, compared to the nonad-
juvanted KLH-alone group (data not shown). Groups admin-
istered KLH and Fx 3, Fx 9, Fx 10, Fx 11, or Fx 12 had higher
anti-KLH serum IgG titers by 3 weeks subsequent to dosing
(200,000) than the CT-adjuvanted group (79,400). As seen
previously with a two-dose regimen, there were no significantly
high anti-KLH secretory IgA titers detected from fecal samples
for any of the groups inoculated with KLH and the Giardia
fractions (data not shown).
Giardia Fx 12, Fx 7, and Fx 2, which had shown measurable
(Fx 12) and negligible (Fx 2 and Fx 7) anti-KLH serum IgG
adjuvant activity, were further assessed for adjuvanticity using
a three-dose inoculation regimen and measurement of anti-
KLH serum antibody titers from individual mice. Peak anti-
KLH serum IgG titers were detected from experiment days 30
to 35 (Fig. 6A), and a peak anti-KLH serum IgA response was
detected on experiment day 30 (Fig. 6B).
Groups administered CT or Fx 12 as adjuvants produced the
strongest anti-KLH serum response (Fig. 6). When average
titers of anti-KLH serum IgG were compared on experiment
day 35, Fx 12 had increased adjuvant activity (94,000) over CT
(27,000) (Fig. 6A). As recorded for 2041 trophozoites as ad-
juvant, the anti-KLH serum IgG response for the Giardia frac-
tion- and CT-adjuvanted groups was strongest for the IgG1
and IgG2b isotypes, with no response detected for the IgG2a
or IgG3 isotypes (data not shown). There was considerable
spread among individual anti-KLH serum IgG titers within the
Fx 2-adjuvanted and KLH-alone groups, with average titers for
these groups (Fx 2, 2,600; KLH, 470) well below those for the
Fx 12- and CT-adjuvanted groups (Fig. 6A).
Average anti-KLH serum IgA titers for the CT- and Fx
12-adjuvanted groups were similar (3,000 to 5,000) on experi-
ment day 30 and considerably higher than those measured for
the Fx 2-adjuvanted and KLH-alone groups (1,000) (Fig.
6B). The Fx 7-adjuvanted group produced one responder
mouse on day 30 with a positive anti-KLH serum IgA titer and
one responder mouse on day 35 with a positive anti-KLH
serum IgG titer. The mean anti-KLH serum IgG and serum
IgA titer for all other mice in the Fx 7-adjuvanted group was
similar to that recorded for the Fx 2-adjuvanted group.
On day 35, significant anti-CT serum IgG titers (65,000 and
6,500) were detected for two mice from the CT-adjuvanted
group, which had the highest anti-KLH serum IgG response.
However, no anti-Giardia serum IgG response was detected in
mouse samples from the Fx 12-adjuvanted group (data not
FIG. 5. Giardia 2041 adjuvants a Flu-specific serum (A) and secre-
tory (B) IgA response. Groups of 8 to 10 C57BL/6J mice were inocu-
lated with 100 g of Flu alone or with Giardia 2041 cytosolic extract
(extracted from 107 trophozoites) or 10 g of CT on days 0, 7, 28, and
42. On day 58, individual serum samples were collected and gut ho-
mogenates were prepared from the excised small intestine of individ-
ual mice. Samples were assayed for the presence of Flu-specific anti-
bodies using ELISA. Results are presented for individual mice, with
the average group titer represented as a bar. Cyt, cytosolic extract.
FIG. 6. Giardia 2041 pooled cytosolic fractions variously adjuvant a
KLH-specific serum IgG (A) and serum IgA (B) response. Groups of
five Quackenbush mice were inoculated with 3 mg of KLH alone or
with Giardia 2041 pooled fractions, each extracted from the equivalent
of 107 trophozoites, or 1 g of CT on days 0, 7, and 21. Individual
mouse serum samples were collected on day 30 (B) and day 35 (A) for
antibody analysis by ELISA. Results are presented for individual mice
in each group, with the average group titer represented as a bar.
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shown), suggesting that the Giardia fraction pool is capable of
augmenting an antigen-specific response without inducing a
detectable response to self, a desirable attribute for effective
adjuvant activity.
DISCUSSION
Cytosolic components of Giardia isolate 2041 cultured tro-
phozoites are capable of adjuvanting an antigen-specific serum
and secretory antibody response to orally coadministered an-
tigen in a mouse model. The Giardia-adjuvanted serum anti-
body response was comparable to that generated by the “gold
standard” mucosal adjuvant, CT. Evidence of enhanced adju-
vant activity induced by isolate 2041 over isolate 106 is consistent
with previous observations of Giardia toxin-like properties (36,
10). We have also confirmed an increased production of total
serum IgA without production of Giardia antigen-specific IgA in
2041-infected mice (36), an ideal attribute of adjuvant activity.
Similarly, our mouse infection model demonstrates Giardia
trophozoite (particularly 2041)-induced secretion of total IgA
in the gut epithelium of neonatal 17-day-old mice, which nor-
mally have an immature immune system in which the processes
of antibody affinity maturation and isotype switching are in
general poorly achieved (19). By 3 weeks of age the neonatal
immune system has matured, and IgA is secreted within the gut
epithelium regardless of incitement (data not shown).
The source of adjuvant activity was localized to the tropho-
zoite cytosol rather than the membrane fraction or secreted
product of the parasite. Although some activity from the se-
creted product might be expected, culture conditions are far
removed from the environment experienced by the parasite in
an animal host and therefore may not be conducive to secre-
tion of toxins or other products. In earlier experiments (data
not shown), proteinase K digestion and 60°C heat treatment of
2041 cytosol reduced adjuvant activity, indicating that a signif-
icant portion of the adjuvant molecule is protein. When dif-
ferent batches of cytosolic extract were used, limited variation
was seen in antigen-specific serum IgG antibody titers. How-
ever, any variability between batches may result from variation
in parasite growth phase, cell count, time of harvest, and vari-
ability in processing.
Both antigen and adjuvant doses play a role in production of
an immune versus a tolerogenic immunological response to
inoculation. Often a large dose of antigen with a strong mu-
cosal adjuvant is required for administration via the oral route
to overcome the phenomenon of oral tolerance (12). Inocula-
tion quantities in experimental studies are usually on the order
of 100 to 5,000 g of antigen and at least 50 g of adjuvant
(22), although smaller quantities (1 to 10 g) of purified CT
(33, 39) and nanogram concentrations of LT (13) have suc-
cessfully adjuvanted a mucosal response. In keeping with these
concentrations, Giardia extracts were administered using the
equivalent of 107 trophozoites, which equates to approximately
500 g (data not shown) of total protein. At this stage we have
not identified what portion of this value can be equated with
the adjuvant factor(s). The quantity of 107 trophozoites was
assessed as the maximum number of trophozoites which colo-
nize a single mouse intestine in the standard laboratory mouse
infection model (32). In an earlier experiment (data not
shown), mice were administered a quarter dose of 2041 cytosol
and KLH antigen, which produced anti-KLH serum IgG titers
at 1.5 weeks subsequent to dosing of up to 200 times less than
those measured with administration of a full dose (equivalent
to 107 trophozoites) of cytosol.
Giardia extracts were administered with a limited range of
KLH concentrations, and a lower limit of 3 to 5 mg per mouse
was determined to be the most suitable concentration for pro-
duction of a strong antigen-specific antibody response compa-
rable to those recorded in the literature (33, 38). When Flu was
administered at a concentration of 100 g per mouse, signifi-
cant anti-Flu serum IgG titers were detected with only the
CT-adjuvanted group and not with the Giardia adjuvants. Av-
erage anti-Flu serum IgA titers were enhanced from the CT-
and Giardia cytosolic extract-adjuvanted groups. Anti-Flu se-
cretory IgA titers varied with the type of secretory extract
tested (fecal, saliva, gut washing, or gut homogenate). The
highest and most consistent titers were measured in the gut
homogenates of the cytosolic extract-adjuvanted groups. High
IgA titers in gut homogenate samples may correlate with the
content of the lamina propria, which is rich in IgA plasma cells
and expected to produce higher antigen-specific titers than gut
washings alone. It is difficult to compare adjuvant activity, on
an equivalent basis, of the crude Giardia extracts with highly
purified and potent CT. Crude Giardia adjuvant activity may
not be of sufficient potency to produce a secretory response in
the less concentrated mucosal samples (fecal and gut washing)
or at distal mucosal sites, e.g., in saliva. The concept of a
common mucosal system where inoculation of a preparation at
one site stimulates a response at all other mucosal sites does
not always follow and may vary with the type of adjuvant
administered (5).
The source of adjuvant activity from Giardia 2041 tropho-
zoites was localized to at least one pool of cytosolic fractions,
fraction pool 12. This fraction pool demonstrated the strongest
adjuvant activity throughout the 3-week postinoculation period
and generated adjuvant activity at a similar level or higher than
the titers recorded for CT. Giardia trophozoites, cytosolic ex-
tract, and fraction pool 12 produced antigen-specific serum
IgG1 and IgG2b isotypes, indicative of a Th2 response. This is
in keeping with the response generated by CT and its mutants,
which primarily stimulate a Th2 response through increased
production of interleukin-4 (IL-4), IL-5, and IL-10, with pre-
dominant production of IgG1 and IgE (22) and in some cases
IgG2b (9) isotypes. This polarization in the T-cell response,
however, varies with adjuvant type and is less pronounced with
LT, which activates both Th1 and Th2 cells (22).
In comparison with other Giardia extracts, and regardless of
dose regimen, we were unable to detect an enhanced antigen-
specific secretory response with administration of the fraction
pools. The ability to adjuvant a secretory response may be
diminished with Giardia protein preparation purification, caus-
ing separation of potent adjuvant complexes. This is not totally
unforeseen, as loss of adjuvant activity has been recorded with
the preparation of mutant molecules of CT and LT, especially
those in which the toxic A1 subunit has been removed (22). If,
like CT, the Giardia adjuvant extracts bind to receptors on the
gut epithelia (22), an alteration in adjuvant structure might
affect its binding ability, therefore preventing transport to im-
mune inductor sites for stimulation of an immune response. It
is possible that more than one form of adjuvant is contained
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within the Giardia trophozoites, with different forms adjuvant-
ing the immune response via a range of mechanisms, which
differentially affect the systemic and mucosal compartments.
We intend to further define the Giardia adjuvant molecule(s),
including its physical properties, which will allow a more direct
comparison by weight with CT and other available adjuvants.
For standard prophylactic immunization in healthy individ-
uals, only adjuvants that induce minimal side effects will prove
acceptable (24). The critical issue of vaccine safety has pre-
cluded many candidate adjuvants from further development
due to their toxic form. Our studies have demonstrated that
extracts produced from the pathogenic Giardia 2041 isolate
function with adjuvant-like activity in an animal model. The
same animals do not display overt behavioral changes synon-
ymous with a toxic response to inoculation, such as reduced
mobility, loss of appetite, and substantial weight loss. These
results indicate that Giardia extracts are worthy of further
investigation as a future source for candidate mucosal and
systemic adjuvants.
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